CLAIMS

1. A compound of formula (I):



(I)

wherein:

Ar is phenyl which can be optionally substituted by one or more groups selected from halogen, hydroxy, cyano, C_1-C_8 alkyl (itself optionally substituted by one or more hydroxy or cyano groups or fluorine atoms), CH_2-R^2; $CH_2O(CH_2)_nOC_{1-6}$ alkyl, C_1-C_8 alkyl-NR^3-R^4;

R^2 is a 5 to 7-membered saturated ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulphur, an aryl or 5- to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from nitrogen oxygen and suphur, each of which can optionally substituted by one or more substituents selected from hydroxyl or hydroxymethyl;

R^3 is hydrogen or C_{1-6} alkyl and R^4 is C_{1-6} alkyl optionally substituted by one or more groups selected from hydroxyl or phenyl,

n is 1 to 4;

R^1 is hydrogen or phenyl optionally substituted by halogen, C_1-C_8 alkoxy, C_1-C_8 thioalkyl or C_1-C_8 alkyl;

and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 in which R^1 is hydrogen or phenyl optionally substituted by halogen, in particular fluoro or bromo.

3. A compound according to claim 1 or 2 in which Ar is a phenyl or a group CH_2R^2 where R^2 is pyrrolidine, morpholine or imidazole each of which is optionally substituted as defined in claim 1

4. A compound according to claim 1 or 2 in which Ar is a group CH_2R^2 where R^2 is pyrrolidine, morpholine or imidazole each of which is optionally substituted by hydroxyl or hydroxymethyl, CH_2NR^3-R^4 where R^3 is hydrogen or methyl and R^4 is CH_2CH_2OH, $CH_2(CH_3)CH_2OH$, CH_2(phenyl)CH_2OH, CH_2CH_2(OH)phenyl, CH_2CH_2(OH)CH_2OH, or $CH_2OCH_2CH_2OCH_2OH$ orAr is phenyl optionally substituted by one or more ethyl or hydroxymethyl groups.

5. A compound according to any one of claims 1 to 3 in which the Ar group is substituted by C_1-C_8 alkyl and C_1-C_8 alkyl substituted by a hydroxy group, more preferably hydroxymethyl.

6. A compound according to claim 1 which is:
4-(2-Ethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-{[(2-hyroxy-ethyl)-methyl-amino]-methyl}-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-1-methyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide
4-{2-Ethyl-3-[(*S*)-(2-hydroxy-1-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-2-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-morpholin-4-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-(3-hydroxy-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-((*R*)-2-hydroxymethyl-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{3-[(2,3-Dihydroxy-propylamino)-methyl]-2-ethyl-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-imidazol-1-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[3-(2-Ethoxy-ethoxymethyl)-2-ethyl-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Bromo-phenyl)-4-(2-ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-hydroxymethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-imidazol-1-ylmethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide
or a pharmaceutically acceptable salt thereof.

7. A compound of formula (I) as defined in any one of claims 1 to 6 for use in therapy

8. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.

9. A method of treating a disease or condition mediate by JAK3 which comprises administering to a patient in need of such treatment a compound of formula (I) as defined in claims 1 to 6 or a pharmaceuticaly acceptable salt thereof.

10. A method according to claim 9 in which the disease or condition is asthma, host versus graft rejection/transplantation or rheumatoid arthritis.

11. A process for the preparation of a compound of formula (I) which comprises: reaction of a compound of formula (II):



(II)

in which R^1 is as defined in formula (I) or is a protected derivatives thereof and L is a leaving group, with a compound of formula (III):

$Ar\text{-}NH_2$ (III)

in which Ar is as defined in formula (I) or is a protected derivatives thereof,
and optionally thereafter:

- removing any protecting groups
- converting a compound of formula (I) into a further compound of formula (I)
- forming a pharmaceutically acceptable salt.